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Background: Neoadjuvant chemoradiotherapy has been newly included in the NCCN guidelines as a treatment
option for stage IIB/III soft tissue sarcomas. Whether radiographic response to neoadjuvant therapy correlates with
improved quality of resection and prognosis remains unproven.
Methods: Data from 120 consecutive patients who were treated with neoadjuvant chemoradiotherapy followed by
surgical resection for their locally aggressive limb sarcomas were retrospectively reviewed. Radiographic response
was evaluated after neoadjuvant therapy according to Response Evaluation Criteria In Solid Tumors, and data was
analyzed for overall survival (OS), local recurrence free survival (LRFS) and metastasis free survival (MFS). Surgical
complications and toxicities, as well as functional outcomes, were also analysed.
Results: After neoadjuvant chemoradiotherapy, 25 patients (20.8%) had a partial response, 75 patients (62.5%) had
stable disease, and 20 patients (16.7%) showed disease progression. Radiographic response to neoadjuvant therapy
correlated significantly with improved OS (P = 0.002) and MFS (P < 0.001). Patients with partial response (PR) had a
significantly decreased rate of R2 resection as compared with stable disease (SD) and progressive disease (PD)
patients (4.0% Vs 21.4%, P < 0.001).
Conclusions: Radiographic response to neoadjuvant chemoradiotherapy correlates with improved quality of
resection and prognosis in extremity STS patients.Background
Soft tissue sarcomas (STS) account for approximately
1% of all adult malignancies [1]. At the time of primary
diagnosis, about 20% of patients have stage IIB/III
disease, as evaluated by American Joint Committee on
Cancer (AJCC) [2]. These tumors are high-grade, >5 cm
in size, deep to investing fascia and are considered high-
risk with a 5-year survival rate of approximately 50% [3].
As reported previously, about 42% of patients with stage
IIB/III STS have extensive or locally advanced sarcomas,
which makes resection with safe margins and satisfactory
functional outcomes very challenging [4]. Treatment mo-
dalities for these patients, as recommended by current* Correspondence: chenyong780417@gmail.com
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stated.National Comprehensive Cancer Network (NCCN) guide-
lines, comprise a multidisciplinary approach of preoperative
chemotherapy and/or radiotherapy (RT) followed by
surgery and adjuvant chemoradiotherapy [5].
Preoperative treatment is now widely used in many
cancers, including STS. Neoadjuvant chemotherapy has
been shown to correlate with improved disease free sur-
vival and overall survival in STS patients [6,7], and pre-
operative radiation has been shown to reduce tumor
burden before resection, allowing more conservative or
function-sparing surgeries [8]. Radiographic response
has been introduced as a useful measure to evaluate
tumor response to preoperative treatment, and has been
correlated with improved local control and overall sur-
vival in a small cohort study [9]. However, whether
radiographic response to neoadjuvant chemotherapy in
high risk STS patients translates into a reduction in the
scope of surgical resection, which would facilitate limb-
salvage operations, remains unanswered. Additionally,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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comes associated with multimodal treatment require fur-
ther investigation.
In this study, we aim to answer whether response to
neoadjuvant therapies correlated wth decreased scope of
surgery and decreased rate of R2 resection in locally ag-
gressive STS. Treatment-related toxicities, functional
outcomes and surgical complications were also reviewed.
We further investigate whether radiographic response to
neoadjuvant therapy correlates significantly with im-
proved overall survival (OS), metastasis free survival
(MFS) and resection quality.
Methods
Patient population
One hundred twenty consecutive patients with locally
aggressive extremity STS of AJCC stage IIB/III who were
treated with neoadjuvant therapy protocol at the TianJin
Medical University Cancer Institute and Hospital
(TJCIH) from 1993 to 2009 represented the study popu-
lation, all patients had at least one vital structures of the
following involved (Encased, partially encircled or infil-
trated) by tumor on presentation: major vessels, vital
nerves and long tubular bones. The study was approved
by institutional review board of TJCIH. Tumor size was
defined as the maximum diameter recorded upon pres-
entation using cross-sectional imaging. Tumors located
in the upper extremities (n = 33) including shoulder
(n = 12) and axilla (n = 10), and lower extremities (n = 87)
including groin (n = 9), hip (n = 11) and buttock (n = 14)
were included. General pathologic features recorded
included tumor size, French Federation of Cancer Centres
(FNCLCC) grade [10], histologic subtype [11] and micro-
scopic margins [12].
Neoadjuvant therapy protocol
The neoadjuvant therapy protocol was administered in a
nonrandomized fashion. All patients had computed tom-
ography (CT) or magnetic resonance imaging (MRI)
studies of their primary lesion before and after neoadju-
vant therapy. All CT scans were performed with intra-
venous contrast enhancement. All MRI studies were
performed with standardized T1 and T2 weighting. The
neoadjuvant therapy protocol was systemic chemother-
apy using a MAID (Mesna + Adriamycin + Ifosfomide +
Dacarbazine) or AIM (Adriamycin + Ifosfomide +Mesna)
regimen for 1 to 2 cycles (Dosage in both regimens: Ifos-
fomide: 2 g/m2 × 5 days; Adriamycin: 30 mg/m2 × 2 days;
Dacarbazine: 400 mg/m2 × 5 days and Mesna: 2 g/m2 ×
5 days). Neoadjuvant chemotherapy regimen choice and
duration were at the discretion of the treating surgical
oncologist based on patient condition, response to first
cycle, or patient decision after cycle 1. Three weeks after
completion of neoadjuvant chemotherapy, radiographicresponse was assessed by CT or MRI using the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria,
and reassessment of resectability was done in accord-
ance with methodology used by Meric et al. [9]. Re-
assessment of tumor size was performed by radiologists
blinded to clinical characteristics, and reassessment of
surgical scope was performed by the surgical oncologist
tasked to perform the resection.
Patients with PR (decrease in scope of surgery) were
assigned to surgical resection without neoadjuvant RT.
Patients with SD (no change in scope of surgery) and pa-
tients with PD (increase in scope of surgery) were
assigned to neoadjuvant RT at dosage of 50Gy (2Gy frac-
tion per day, 5 days per week for 5 successive weeks),
given until completion, patient refusal, or unacceptable
RT-related toxicities. Neoadjuvant RT was followed by
the same imaging studies, reassessment and operations
as for all other patients.
The National Cancer Institute Common Toxicity
Criteria, version 3.0, were used to assess chemotherapy-
related toxicity and the Radiation Therapy Oncology
Group (RTOG) acute and chronic toxicity criteria were
used to describe toxicity due to RT [13].
Surgery and post-operative treatment
All one hundred and twenty patients underwent surgical
resection 3 to 4 weeks after completion of neoadjuvant
therapy. A decreased scope of surgery was acknowledged
by multidisciplinary team that one or more vital struc-
ture could be spared or more normal tissue could be
preserved (PR) after neoadjuvant therapies. In patients
with tumor response (PR) to neoadjuvant therapies, limb
salvage surgical resection was performed per normal
clinical practice through grossly normal tissues. In pa-
tients wth SD after neoadjuvant therapies, limb-salvage
surgical resection with reconstruction was perfomed as
following: If the tumor was found during surgery to abut
a major vascular structure, resection and reconstruction
of the vasculature were performed with autograft or arti-
ficial vessels. If the tumor invaded bone shaft, major
bone resection and reconstruction were performed with
implantable endoprostheses or plate and screws. If the
tumor surrounded or compressed a major nerve, the
epineurium was removed in continuity with the tumor
and the nerve was treated with anhydrous alcohol for
20 minutes intra-operatively. Moreover, vascular or rota-
tional musculocutaneous flap was applied when neces-
sary. Patients with PD even after neoadjuvant chemo
and radiotherapy were assigned to amputation if con-
senting. Some patients with PD chose limb-salvage oper-
ations despite risk of R2 resection.
Post-operative chemotherapy consisted of MAID or
AIM at same dosage as preoperative regimens for pa-
tients with PR or SD and second line chemotherapy
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tabine + docetaxel for others) for patients with PD after
neoadjuvant therapy. For both groups, adjuvant chemo-
therapy was administered every 3 weeks for 2 cycles,
followed by adjuvant radiotherapy, and 2 more cycles of
chemotherapy.
Adjuvant radiotherapy was administered to primary
tumor site after completion of two cycles of adjuvant
chemotherapy, but within first 3 post-operative months
for all patients undergoing limb-salvaging surgeries,
unless patients refused or demonstrated unacceptable
RT-related toxicities. Some patients received RT both
before and after surgery, the dosage was based on previ-
ous neoadjuvant radiotherapy and should not exceed a
total of 6500 cGy per patient.
Post-treatment followup was performed every 3 months
for the first 2 years after surgery, then twice annually for
2–3 years, and once annually thereafter. Surgical complica-
tions were evaluated as proposed by Daniel et al. according
to a 5-level grading system [14]. In brief, the complications
were graded according to the treatment modalities and
adverse results to the patients. For instance, grade 1 refers
to a situation that requires a bedside debridement of
wound, grade 2 is an unexpeted bleeding which result in
prolonged hospitalization, grade 3 refers to re-operation,
grade 4 is perioperative lost of organ or extremity, and
grade 5 refers to death. Evaluation of function for the in-
volved extremity was performed using the Functional
Evaluation System proposed by Enneking et al. [15], in
which patients assessed their pain, function, emotional
acceptance, supports, walking, and gait, each on a scale of 0
(worst) to 5 (best) points for a maximum of 30 points.
Statistics
SPSS 13.0 software was used for statistical analysis. OS,
LRFS and MFS were calculated using the Kaplan-Meier
method [16]. OS, LRFS, and MFS were defined as the
interval from the beginning of treatment to death, to the
first local recurrence, and to the first metastasis, respect-
ively. Patients who died from causes unrelated to sar-
coma were censored at the time of death. Univariate and
multivariate prognostic analyses were performed for OS,
LRFS and MFS using the Cox proportional hazards
models [17]. The statistically significant variables in the
univariate analysis were retained in both multivariate
analyses. The conventional 5% significance level was
used.
Results
Clinical characteristics, pathologic features and
treatment modalities
Clinical, pathologic, and treatment variables, and their
correlation with radiographic response for all 120 pa-
tients are listed in Table 1. Neoadjuvant chemotherapyresulted in 25 cases of PR, 75 cases of SD and 20 cases
of PD. Using the RECIST criteria, none of the 95 pa-
tients who underwent neoadjuvant radiotherapy demon-
strated a complete response (CR) or PR. All patients
with tumor response of SD to neoadjuvant chemother-
apy demonstrated SD after neoadjuvant radiotherapy. Of
the 20 patients with PD after neoadjuvant chemotherapy,
14 had SD and 6 had PD after neoadjuvant radiotherapy.
On presentation, all 120 patients were evaluated to
have amputation as only choice (n = 30) or have to
undergo vessel replacement (n = 79) and bony recon-
struction (n = 11), 30 patients of the 79 were evaluated
to be candidates of epineural resection (n = 30). All 120
patients underwent surgical resection 3 to 4 weeks after
completion of neoadjuvant therapy. In patients with
tumor response of PR or SD, limb salvage surgical
resection was performed (n = 100/120). Patients with PD
(n = 20/120) were recommended to undergo amputation
because of extensive tumor growth and neurovascular
bundle invasion, but only 11/20 patients accepted, while
9/20 patients with PD chose limb-salvage operations des-
pite the risk of R2 resection. In total 109 patients under-
went limb salvage resections, 55/109 (50.6%) underwent
resection without reconstruction, 54/109 (49.4%) had resec-
tion with other modalities such as autograft or artificial ves-
sel replacement due to resection of major vessels (n = 33),
inner fixation due to resection of bony structures (n = 11)
or epineural dissection and anhydrous alcohol implication
due to proximity of major nerves to tumor (n = 20).
All 120 patients were treated with adjuvant chemo-
therapy according to hospital protocol. Gemcitabine +
docetaxel was administered to 17 patients while 3 pa-
tients received high dose ifosfamide. In all 109 patients
who underwent limb-salvage operations, 95 patients had
radiotherapy both before and after surgery, with a total
dose of 6500 cGy, 14 patients underwent post-operative
external beam radiotherapy only (400 cGy fraction per
day, 5 days per week for successive 4 weeks) with a total
dose of 6500 cGy.Complications and toxicities
There was no treatment associated death in this study.
One patient had a grade IV surgical complication of
acute arterial embolization in the lower femoral artery
by the second post-operative day and was treated with
above knee amputation. Nine patients (9/120, 7.5%) had
grade III surgical complications and had re-operations.
Grade II and grade I surgical complications were seen in
20 (16.7%) and 22 (18.3%) patients respectively, with
most of the cases well managed with additional antibi-
otics and debridements at the bedside. Altogether, surgi-
cal complications were seen in 52 patients (43.3%) in
our study, most of these were mild to moderate,
Table 1 The clinical, pathologic, treatment characteristics in patients with stage III STS and their correlations with
radiographic response
Issues Catogaries N Radiographic response χ P
PR SD PD
Age Median 42 years
Gender Male 67 15 39 13 −0.02 0.831
Female 53 10 36 7
Size(CM) Mean 10 cm
≥10 5 39 19 0.453 <0.001
<10 20 36 1
FNCLCC grade 2 45 10 31 4 3.150 0.207
3 75 15 44 16
Subtype MFH 33 6 17 10 11.270 0.187
SS 28 5 20 3
LS 28 8 16 4
LMS 16 1 13 2
Others 15 5 9 1
Neo-AC cycles 1 18 7 10 3 0.832 0.374
2 102 18 65 17
Chemotherapy regimen MAID 80 18 50 12 0.720 0.698
AIM 40 7 25 8
UICC margin R0 + R1 92 24 57 11 10.491 0.005
R2 28 1 18 9
Follow-up(M) Median 46.0 (13–158)
PR: Partial response; SD: Stable Disease; PD: Progressive Disease; FNCLCC: French Federation of Cancer Centres; Neo-AC: Neoadjuvant chemotherapy; UICC: Union
Internationale Contre Cancer; MFH: malignant fibrous histiocytoma; SS: synovial sarcoma; LS: liposarcoma; LMS: leiomyosarcoma.
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feasible and safe.
Forty-one out of 120 patients (34.2%) in total experienced
grade 4 toxicities due to chemo- or radiotherapy; thirth-
four patients (28.3%) experienced grade 4 hematologic
toxicities, and ten patients (8.3%) experienced grade 4
nonhematologic toxicities. Chemo-associated toxicities
included grade 4 leukopenia in twenty-seven, grade 4
thrombocytopenia in twelve, grade 4 anemia in six,
grade 4 liver function toxicities in two and grade 4
nausea and vomiting in two. Radio-associated toxicities
included grade 4 RT-associated cutaneous ulceration
and infection in four and femoral shaft fracture at the
site of post-operative radiotherapy in two. Three pa-
tients had both grade 4 chemo-associated and radio-
associated toxicities.
Response to neoadjuvant therapy correlated with decreased
scope of surgery in locally aggressive extremity STS patients
with acceptable functional outcomes
We first investigated whether response to neoadjuvant
chemoradiotherapy correlated with decreased scope of
surgery in patients with extensive or locally advancedsarcomas. After neoadjuvant therapy, 20/120 patients
who had PD were recommended to undergo ablative
procedures, of which 11 agreed and 9 chose to undergo
limb-salvage operations. In total 109 patients underwent
a limb-salvaging operation. Though 28 (28/109, 25.7%)
of these limb-salvage patients had a R2 resection, the
tumor regression in the 25 patients (25/120, 20.8%) with
PR to neoadjuvant chemotherapy translated into de-
crease in scope of surgery. More precisely, in the 30 pa-
tients who were evaluated on presentation to have only
amputation as treatment choice, 12 of them had PD and
were recommended amputation (8 accepted and 4
refused), 12 others had SD and underwent tumor resec-
tion with reconstruction (vessel replacement in 6, epi-
neural resection in 4 and both in 2), the remaining 6
patients had PR and underwent tumor resection without
sacrifice of vital structures. Furthermore, in the 79
patients who had vascular involvement on presentation
which surgeons would recommend vascular resection, all
those presented PR (n = 13) and 33 of 58 who presented
SD (33/58, 56.9%) to neoadjuvant therapies had their ves-
sels spared. The above findings indicated that neoadju-
vant chemotherapy might play a role in limb-salvage
Figure 1 Left panel: Kaplan-Meier curves of overall survival (OS) according to radiographic response. Right panel: cumulative incidence
curves of risk of death.
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the other hand, the 75 SD patients who had their diseases
evaluated before neoadjuvant therapies to be unresect-
able were treated with limb-salvage operation, with 18 of
the 75 (18/75, 24%) were R2 resection.
We further evaluated post-operative function in limb-
salvage patients with MSTS scoring system. The mean
score was 26 (87% score, range 16–28), indicating good
functional outcomes in these patients, especially consid-
ering their poor prognosis on presentation.
Radiographic response to neoadjuvant therapy is of
prognostic value in patients with stage IIB/III STS
We hypothesized that any decrease in tumor size after




PR (n = 25) 96.0 0.081 0
SD + PD (n = 95) 38.8 1
Size (cm)
≥10 (n = 63) 33.5 5.276 2
<10 (n = 57) 81.4 1
FNCLCC Grade
Grade 2 (n = 45) 86.2 1
Grade 3 (n = 75) 38.7 6.188 2
UICC margins
R0 + R1 (n = 92) 69.9 1
R2 (n = 28) 6.6 8.196 4
Surgery type
Resection only (n = 55) 89.4 1
Resection with other modalities* (n = 65) 26.9 9.708 4
*: Other modalities include epineural dissection and reconstruction of blood vessels
Union Internationale Contre Cancer.Therefore, patients who had radiographic PR were
compared with patients who had SD and PD. In univari-
ate analysis, radiographic response correlated with im-
proved OS (Figure 1, Table 2), LRFS (Figure 2, Table 3)
and MFS (Figure 3, Table 4). In multivariate analysis,
response of PR correlated significantly with OS (HR,
0.133; 95% CI, 0.037-0.483; P = 0.002) and MFS (HR,
0.098; 95% CI, 0.030-0.317; P < 0.001). Patients with PR
also had improved LRFS (HR, 0.366; 95% CI, 0.044-3.027)
compared with those with SD and PD, but the difference
did not reach statistical significance (P = 0.351).
Furthermore, we investigated the impact of radiographic
response on resection margin. In the 109 patients who
underwent limb-salvaging procedures, resection margin
was R2 in 28 patients. For patients with PR (n = 25), SDrs for 5-year OS
ariate analysis Multivariate analysis
95% CI P RR 95% CI P
<0.001














and bony structures. FNCLCC: French Federation of Cancer Centres; UICC:
Figure 2 Left panel: Kaplan-Meier curves of local recurrence free survival (LRFS) according to radiographic response. Right panel:
cumulative incidence curves of risk of local recurrence.
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be R2 in 1, 18 and 9 patients (P < 0.001) respectively, indi-
cating that radiographic response correlated with improved
quality of resection in these patients.
Discussion
The goal of surgical therapy for soft tissue sarcoma is to
achieve grossly and microscopically negative (R0) mar-
gins of resection with the best possible functional re-
sults. Our study retrospectively reviewed full data of 120
consecutive cases who had locally advanced sarcomas
and were treated with neoadjvuant therapy and surgical
resection. We demonstrated that 109 (90.8%) patients
underwent a limb-salvaging procedure after neoadjuvant




PR (n = 25) 96.0 0.100
SD + PD (n = 95) 65.0 1
Size (cm)
≥10 (n = 63) 33.3 6.614 2
<10 (n = 57) 81.4 1
FNCLCC Grade
Grade 2 (n = 45) 86.2 1
Grade 3 (n = 75) 38.6 9.178 2
UICC margins
R0 + R1 (n = 92) 69.9 1
R2 (n = 28) 6.6 22.975 9
Surgery type
Resection only (n = 55) 89.4 1
Resection with other modalities* (n = 65) 27.1 9.184 2
*: Other modalities include epineural dissection and reconstruction of blood vessels
Union Internationale Contre Cancer.(9.2%, 11/120). Though many patients in this series
underwent vascular reconstruction, bony reconstruction
or perineural dissection, which were key to limb-salvage,
radiographic response to neoadjuvant therapies corre-
lated significantly with increased rate of limb-salvage re-
sections (with acceptable function) and with better
resection quality. Survival analysis indicated that radio-
graphic response correlated with improved OS, LRFS
and MFS, which was in accordance with a previous
report of a smaller cohort of patients [9]. As previous
data failed to show that neoadjuvant chemotherapy fa-
cilitates limb-salvage operation, our study presented,
though retrospective, evidence supporting the use of
neoadjuvant therapy in patients who are candidates of
amputation.rs for 5-year local recurrence free survival (LRFS)
ariate analysis Multivariate analysis
















and bony structures. FNCLCC: French Federation of Cancer Centres; UICC:
Figure 3 Left panel: Kaplan-Meier curves of metastasis free survival (MFS) according to radiographic response. Right panel: cumulative
incidence curves of risk of metastasis.
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cologists and radiologists because it is the most import-
ant determinant of resection quality, reconstruction and
scope of adjuvant radiotherapy. Decreased scope of sur-
gery is also associated with better functional outcomes
and decreased morbidities [18,19], hence, a decrease in
scope of surgery has a positive impact on patients' prog-
nosis. Efforts have been made to obtain tumor shrinkage
or compartmental limitation in patients with locally ad-
vanced STS. Of the available techniques, isolated limb
perfusion (ILP) and neoadjuvant chemoradiotherapy are
recommended by the current NCCN guidelines. How-
ever, there is no persuasive data to show that ILP has an
impact on OS, while neoadjuvant chemoradiotherapy




PR (n = 25) 96.0 0.072 0
SD + PD (n = 95) 30.9 1
Size (cm)
≥10 (n = 63) 29.0 3.098 1
<10 (n = 57) 67.9 1
FNCLCC Grade
Grade 2 (n = 45) 70.2 1
Grade 3 (n = 75) 33.9 2.938 1
UICC margins
R0 + R1 (n = 92) 60.6 1
R2 (n = 28) 3.6 5.995 3
Surgery type
Resection only (n = 55) 75.8 1
Resection with other modalities* (n = 65) 22.8 4.882 2
*: Other modalities include epineural dissection and reconstruction of blood vessels
Union Internationale Contre Cancer.high risk extremity STS patients even over a long-term
followup [7,20].
Radiographic evaluation of tumor response to neoad-
juvant therapy provides a non-invasive preoperative mo-
dality to predict local outcome and survival. After
induction therapy, radiographic examination of the pri-
mary tumor is also necessary to create a surgical plan
[21]. Recently, the reliability of radiographic response
(CT or MRI) as a prognostic tool has been questioned
[18], pre-operative positron emission tomography (PET)
or post-operative pathologic necrosis were introduced
to assess response to pre-operative therapy [22,23],
but pathologic necrosis can only be evaluated post-
operatively, thus has no predictive value for scope of
surgery and functional outcome, while PET is veryrs for 5-year metastasis free survival (MFS)
ariate analysis Multivariate analysis
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ited [24,25], furthermore, it is of limited help for surgical
planning–- surgeons will resect all possible lesions even
if PET indicates they are inactive. MRI or CT give the
same data as PET for planning surgical scope, but are
far cheaper. Thus, the practical feasibility and cost-
effectiveness of using CT or MRI vs PET for radio-
graphic evaluation of tumor response to neoadjuvant
therapies favors their routine use as a prognostic tool in
cancer centers, especially those in developing countries.
Patients with radiographic response of PR or SD to
neoadjuvant therapies were all considered to have
clinical benefit from treatment according to RECIST
criterion. In our study, we found that patients with
radiographically-determined PD had poorer prognosis
compared to that of patients with SD or PR, this finding
may be explained by three factors. First, it is accepted
that quality of surgical margins independently predicts
local control and survival [26]. It is a challenge for surgi-
cal oncologists to obtain a safe margin in limb-salvage
operations for patients with stage IIB/III STS, especially
those with PD to induction therapies. Nine of the 20 pa-
tients who had PD in our series underwent limb-salvage
resection, all with a positive margin and poor prognosis.
Second, rapidly growing sarcomas with largest diameter
more than 10 cm are prone to have intra-operative
tumor rupture, which was proven recently to predict
early metastasis [4]. In all patients (n = 69) who devel-
oped systemic metastases in our study, 19 patients (1, 9
and 9 had PR, SD and PD, respectively) had tumor rup-
ture intra-operatively. These patients developed systemic
metastases in a median interval of 5 months (range
2–12), while patients without intra-operative tumor rup-
ture developed metastases in a median interval of
21 months (range 6–98, P < 0.001). Third, response to
systemic therapy has been proven effective in extending
progression free survival and OS in metastatic STS [27],
while neoadjuvant chemotherapy was reported to associ-
ate with improved disease free survival and OS [7]. The
20 patients with PD to neoadjuvant chemoradiotherapy
presented significantly worse OS, MFS and median post-
metastasis survival (17 months vs 22 months, P = 0.002)
compared with that in patients with SD or PR. This is in
accordance with Delaney’s study [7].
The main limitation of this study is its retrospective
nature and a small sample size without comparison
group. Furthermore, radiographic response evaluated by
CT or MRI according to RECIST criteria was based on
tumor size alone, and such measures are unable to show
changes within the tumor. Cases with extensive liquefy-
ing necrosis as a result of induction therapy, which were
evaluated as SD or even PD in our preoperative evaluation,
might also facilitate a limb-salvage resection because of de-
creased tumor capsule tension and peri-capsule edema.Thus, combination with evaluation of tumor necrosis after
induction therapy might improve the sensitivity and speci-
ficity of using radiographic response as an evaluation tool.
Conclusions
In locally advanced extremity STS patients, response to
neoadjuvant chemo and radiotherapy (21% in our study)
might associate with improved survival and quality of
surgical resection, but more active agents or regimens
are needed for patients who do not have a radiographic
response to induction therapies (79% of patients in our
study). Developments in molecular biology may help
identify which patients will respond best to chemo and
radiotherapy and further increase response rates.
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